{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:20:21Z","timestamp":1790104821040,"version":"4.0.1"},"reference-count":90,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2025,4,13]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>The fifth edition of the WHO classification of haematolymphoid tumours (WHO-HEM5) introduces significant updates to the classification of acute lymphoblastic leukaemia, ALAL (including mixed phenotype acute leukaemia (MPAL)), myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK), and histiocytic and dendritic cell neoplasms, reflecting the advances in the understanding of the genetic basis of these diseases. This review provides an overview of these changes, highlighting a shift to a more refined molecular-genetic approach. The incorporation of newly recognised genetic subtypes into the classification scheme underscores the evolving landscape of these entities. Challenges in diagnosing ALAL\/MPAL and MLN-TK are discussed, along with recent insights into histiocytic and dendritic cell neoplasms, including newly defined entities such as ALK-positive histiocytosis.<\/jats:p>\n               <jats:p>The review also explores the practical implications of WHO-HEM5, particularly in resource-limited settings, where comprehensive molecular testing may be unavailable. While morphology and immunohistochemistry remain essential diagnostic tools, strategic use of flow cytometry and targeted fluorescence in situ hybridisation can facilitate risk-adapted classification and improve survival in regions with limited resources and therapeutic options. Future large-scale studies are necessary to establish the diagnostic and prognostic value of these newly genetically defined entities for diverse healthcare environments, and to standardise guidelines in refining disease classification and optimising patient outcomes.<\/jats:p>","DOI":"10.1136\/jcp-2025-210135","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T03:35:15Z","timestamp":1746243315000},"page":"505-518","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Fifth edition WHO classification: precursor lymphoid neoplasms, acute leukaemias of mixed or ambiguous lineage, myeloid\/lymphoid neoplasms, and histiocytic and dendritic cell neoplasms, including strategies for application in resource-limited settings"],"prefix":"10.1136","volume":"78","author":[{"given":"Prashant","family":"Tembhare","sequence":"first","affiliation":[{"name":"Hematopathology Department, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Section of Pathology, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"},{"name":"Department of Laboratory Medicine & Pathology, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K C","family":"Chan","sequence":"additional","affiliation":[{"name":"Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Wood","sequence":"additional","affiliation":[{"name":"Diagnostic Immunology & Flow Cytometry, Children\u2019s Hospital Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-3638","authenticated-orcid":false,"given":"Kikkeri N","family":"Naresh","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathology, University of Washington, Seattle, Washington, USA"},{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"2025092503395542000_78.8.505.1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15785"},{"key":"2025092503395542000_78.8.505.2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14617"},{"key":"2025092503395542000_78.8.505.3","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-021-01043-9","article-title":"Childhood Acute Leukemias in Developing Nations: Successes and Challenges","volume":"23","author":"Zapata-Tarr\u00e9s","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2025092503395542000_78.8.505.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00577","article-title":"Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients","volume":"10","author":"Tembhare","year":"2020","journal-title":"Front Oncol"},{"key":"2025092503395542000_78.8.505.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2025092503395542000_78.8.505.6","first-page":"6","article-title":"Method for DNA Ploidy Analysis Along with Immunophenotyping for Rare Populations in a Sample using FxCycle Violet","volume":"80","author":"Tembhare","year":"2017","journal-title":"Curr Protoc Cytom"},{"key":"2025092503395542000_78.8.505.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-389932"},{"key":"2025092503395542000_78.8.505.8","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22858"},{"key":"2025092503395542000_78.8.505.9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.214353"},{"key":"2025092503395542000_78.8.505.10","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27366","article-title":"A triple-probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings","volume":"65","author":"Parihar","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2025092503395542000_78.8.505.11","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3362"},{"key":"2025092503395542000_78.8.505.12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011346"},{"key":"2025092503395542000_78.8.505.13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11790","article-title":"Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia","volume":"7","author":"Lilljebj\u00f6rn","year":"2016","journal-title":"Nat Commun"},{"key":"2025092503395542000_78.8.505.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-382861"},{"key":"2025092503395542000_78.8.505.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010144"},{"key":"2025092503395542000_78.8.505.16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12042"},{"key":"2025092503395542000_78.8.505.17","doi-asserted-by":"publisher","DOI":"10.1111\/his.14176"},{"key":"2025092503395542000_78.8.505.18","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21845"},{"key":"2025092503395542000_78.8.505.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"2025092503395542000_78.8.505.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0436-0"},{"key":"2025092503395542000_78.8.505.21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0145"},{"key":"2025092503395542000_78.8.505.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150841"},{"key":"2025092503395542000_78.8.505.23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17210"},{"key":"2025092503395542000_78.8.505.24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12277"},{"key":"2025092503395542000_78.8.505.25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cyto.b.21072","article-title":"A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin","volume":"84","author":"van den Ancker","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"key":"2025092503395542000_78.8.505.26","doi-asserted-by":"publisher","DOI":"10.1002\/cytob.21129"},{"key":"2025092503395542000_78.8.505.27","first-page":"2275","article-title":"The International Consensus Classification of acute leukemias of ambiguous lineage","volume":"141","author":"Weinberg","year":"2023","journal-title":"Blood"},{"key":"2025092503395542000_78.8.505.28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/ijlh.13923","article-title":"To B- or not to B-: A review of lineage switched acute leukemia","volume":"44 Suppl 1","author":"Kurzer","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"2025092503395542000_78.8.505.29","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3324\/haematol.2020.250423","article-title":"DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch","volume":"106","author":"Novakova","year":"2021","journal-title":"Haematologica"},{"key":"2025092503395542000_78.8.505.30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007423"},{"key":"2025092503395542000_78.8.505.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"key":"2025092503395542000_78.8.505.32","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27265","article-title":"Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia","volume":"65","author":"Oberley","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2025092503395542000_78.8.505.33","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25953"},{"key":"2025092503395542000_78.8.505.34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782888"},{"key":"2025092503395542000_78.8.505.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30459-8"},{"key":"2025092503395542000_78.8.505.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30460-4"},{"key":"2025092503395542000_78.8.505.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0058-4"},{"key":"2025092503395542000_78.8.505.38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-821363"},{"key":"2025092503395542000_78.8.505.39","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32552"},{"key":"2025092503395542000_78.8.505.40","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25825"},{"key":"2025092503395542000_78.8.505.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0165-9"},{"key":"2025092503395542000_78.8.505.42","first-page":"614","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia\/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition","volume":"106","author":"Yao","year":"2021","journal-title":"Haematologica"},{"key":"2025092503395542000_78.8.505.43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004174"},{"key":"2025092503395542000_78.8.505.44","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001282"},{"key":"2025092503395542000_78.8.505.45","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.11","article-title":"Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion","volume":"6","author":"Telford","year":"2016","journal-title":"Blood Cancer J"},{"key":"2025092503395542000_78.8.505.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2023.09.007"},{"key":"2025092503395542000_78.8.505.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0653-6"},{"key":"2025092503395542000_78.8.505.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1012-y"},{"key":"2025092503395542000_78.8.505.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.08.007"},{"key":"2025092503395542000_78.8.505.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00311-1"},{"key":"2025092503395542000_78.8.505.51","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41572-021-00307-9","article-title":"Histiocytic disorders","volume":"7","author":"McClain","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025092503395542000_78.8.505.52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013338"},{"key":"2025092503395542000_78.8.505.53","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199101000-00011"},{"key":"2025092503395542000_78.8.505.54","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199002000-00001"},{"key":"2025092503395542000_78.8.505.55","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000156"},{"key":"2025092503395542000_78.8.505.56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117531"},{"key":"2025092503395542000_78.8.505.57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3297"},{"key":"2025092503395542000_78.8.505.58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-447599"},{"key":"2025092503395542000_78.8.505.59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007897"},{"key":"2025092503395542000_78.8.505.60","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.3390\/cancers14143375","article-title":"Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025092503395542000_78.8.505.61","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0154-5"},{"key":"2025092503395542000_78.8.505.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.01.010"},{"key":"2025092503395542000_78.8.505.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815105"},{"key":"2025092503395542000_78.8.505.64","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006645"},{"key":"2025092503395542000_78.8.505.65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00456"},{"key":"2025092503395542000_78.8.505.66","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13541"},{"key":"2025092503395542000_78.8.505.67","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31818593d6"},{"key":"2025092503395542000_78.8.505.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2015.02.008"},{"key":"2025092503395542000_78.8.505.69","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13017"},{"key":"2025092503395542000_78.8.505.70","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850515)55:10<2417::AID-CNCR2820551020>3.0.CO;2-9"},{"key":"2025092503395542000_78.8.505.71","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200305000-00003"},{"key":"2025092503395542000_78.8.505.72","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000147395.01229.06"},{"key":"2025092503395542000_78.8.505.73","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14174"},{"key":"2025092503395542000_78.8.505.74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-430140"},{"key":"2025092503395542000_78.8.505.75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-690636"},{"key":"2025092503395542000_78.8.505.76","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.160"},{"key":"2025092503395542000_78.8.505.77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713676"},{"key":"2025092503395542000_78.8.505.78","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a034892","article-title":"MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age","volume":"11","author":"Chakraborty","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025092503395542000_78.8.505.79","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0168-6"},{"key":"2025092503395542000_78.8.505.80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147017"},{"key":"2025092503395542000_78.8.505.81","doi-asserted-by":"publisher","DOI":"10.1177\/1093526617740784"},{"key":"2025092503395542000_78.8.505.82","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-02027-7"},{"key":"2025092503395542000_78.8.505.83","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001567"},{"key":"2025092503395542000_78.8.505.84","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001794"},{"key":"2025092503395542000_78.8.505.85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124792"},{"key":"2025092503395542000_78.8.505.86","doi-asserted-by":"publisher","DOI":"10.2350\/09-03-0622-OA.1"},{"key":"2025092503395542000_78.8.505.87","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.102"},{"key":"2025092503395542000_78.8.505.88","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00673-x"},{"key":"2025092503395542000_78.8.505.89","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.167"},{"key":"2025092503395542000_78.8.505.90","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02691-w"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2025-210135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:40:05Z","timestamp":1758796805000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2025-210135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":90,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,7,18]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/jcp-2025-210135"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2025-210135","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]}}}